Table 2.

Immunosuppressing conditions and comorbidities of visceral leishmaniasis patients diagnosed in public hospitals in Mainland Portugal in 2010–2020

Immunosuppression, % (n)
Yes	60.6
Yes	(134/221)
Unknown/Not reported	8.1
Unknown/Not reported	(18/221)
HIV infection/AIDS
Yes, % (n)	53.5
Yes, % (n)	(108/202)
Median CD4 cell count, /µL (IQI)	59.0
Median CD4 cell count, /µL (IQI)	[21.5–127.0]
CD4 cell count < 200/µL, % (n)	85.1
CD4 cell count < 200/µL, % (n)	(86/101)
Detectable viral load, % (n)	65.6
Detectable viral load, % (n)	(63/96)
Median viral load, cp/mL (IQI)	80,000
Median viral load, cp/mL (IQI)	[220–631,400]
Chronic pharmacologic immunosuppression, % ( n )
Inflammatory/autoimmune diseases	10.8
Inflammatory/autoimmune diseases	(21/194)
Anti-TNFα containing regimen	11.8
Anti-TNFα containing regimen	(2/17)
Methotrexate ± corticosteroid	58.8
Methotrexate ± corticosteroid	(10/17)
Isolated corticosteroid	23.5
Isolated corticosteroid	(4/17)
Other^a	5.9
Other^a	(1/17)
Solid organ transplant^b	2.3
Solid organ transplant^b	(4/173)
Chronic dysfunction/condition, % ( n )
Diabetes mellitus	7.9
Diabetes mellitus	(14/178)
Chronic kidney disease	12.5
Chronic kidney disease	(22/178)
Chronic liver disease	13.3
Chronic liver disease	(24/181)
Chronic pulmonary disease	5.1
Chronic pulmonary disease	(9/178)
Chronic heart failure	3.9
Chronic heart failure	(7/181)

IQI Interquartile interval, HIV Human immunodeficiency virus, AIDS Acquired Immunodeficiency syndrome, TNF Tumor Necrosis Factor

^aAzathioprine + corticosteroid n = 1, mycophenolate mofetil + corticosteroid n = 1

^bKidney n = 3, liver n = 1